Zobrazeno 1 - 10
of 81
pro vyhledávání: '"RAHUL S. DALAL"'
Autor:
RAHUL S. DALAL, DEBORAH C. RUBIN
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 5, Pp 743-744 (2023)
Externí odkaz:
https://doaj.org/article/dfd76fad2a364fb394e5c532f416dee6
Publikováno v:
Brazilian Journal of Cardiovascular Surgery, Vol 30, Iss 5, Pp 520-532 (2015)
ABSTRACT OBJECTIVE: Atrial fibrillation and neurocognitive decline are common complications after cardiopulmonary bypass. By utilizing genomic microarrays we investigate whether gene expression is associated with postoperative atrial fibrillation and
Externí odkaz:
https://doaj.org/article/931fe279066b4ad5a849f99443f65a32
Publikováno v:
Digestive Diseases and Sciences. 68:1709-1713
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4bad42efac931b5604bada0c68880b5
https://doi.org/10.1007/s10620-023-07866-9
https://doi.org/10.1007/s10620-023-07866-9
Publikováno v:
Inflammatory Bowel Diseases. 29:830-833
Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d2c3f38d8a8a4557fcf9cbc1e3265a
https://doi.org/10.1093/ibd/izac164
https://doi.org/10.1093/ibd/izac164
Publikováno v:
Inflammatory Bowel Diseases.
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Real-world data comparing the effectiveness of tofacitinib to ustekinumab are limited. We compared 52-week outcomes of tofacitinib vs ustekinumab f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::653457de3400dc7b74ca5dce1ec7360f
https://doi.org/10.1093/ibd/izad087
https://doi.org/10.1093/ibd/izad087
Publikováno v:
Digestive Diseases and Sciences. 68:223-232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a7ae2178e48e5c70baac1ad351855a1
https://doi.org/10.1007/s10620-022-07472-1
https://doi.org/10.1007/s10620-022-07472-1
Publikováno v:
Inflammatory Bowel Diseases. 28:1787-1789
Lay Summary In this case series, 6 patients with chronic pouchitis (n = 3), cuffitis (n = 2), or Crohn’s-like disease of the pouch (n = 1) were treated with tofacitinib. One patient achieved clinical response; however, all patients ultimately disco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43b9fabfbead7a0ff9dfe78fb6547214
https://doi.org/10.1093/ibd/izac147
https://doi.org/10.1093/ibd/izac147
Publikováno v:
Inflamm Bowel Dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b5df7397859ca8f5f45c8c71bc1b64
https://doi.org/10.1093/ibd/izab156
https://doi.org/10.1093/ibd/izab156
Autor:
James N. Gerson, Ravy K. Vajravelu, Rahul S. Dalal, Abraham Segura, James D. Lewis, Meghana Golla, Nadim Mahmud
Publikováno v:
Dig Dis Sci
BACKGROUND: Patients with recent hematopoietic cell transplantation (HCT) are considered high risk for gastrointestinal endoscopy due to the potential for procedural bacterial translocation. Prior studies investigating these risks do not account for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3838e7aea5f1e038831707d1ad161db4
https://doi.org/10.1007/s10620-021-07062-7
https://doi.org/10.1007/s10620-021-07062-7
Publikováno v:
Inflamm Bowel Dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c5c426205682114817139ab00f81867
https://doi.org/10.1093/ibd/izab097
https://doi.org/10.1093/ibd/izab097